



Express Mail No.: EV473971339US  
Sheet 1 of 3

LIST OF REFERENCES CITED BY APPLICANT  
(Use several sheets if necessary)

ATTY. DOCKET NO. 6750-189-999	APPLICATION NO. 10/567,702
APPLICANT	
Richard Kim	

U.S. FILING DATE August 21, 2006	ART UNIT 1642
-------------------------------------	------------------

**U.S. PATENT DOCUMENTS**

Examiner Initial	Document Number	Date mm/dd/yy	Name Of Patentee Or Applicant Of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear

**FOREIGN PATENT DOCUMENTS**

	Foreign Patent Document Country Code, Number, Kind Code (If Known)	Date mm/dd/yy	Name Of Patentee Or Applicant Of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	(Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue number(s), publisher, city and/or country where published)	T
C01	AARANSON, 1991, "Growth factors and cancer." <i>Science</i> 254:1146-53	
C02	BASELGA et al., 2001, "Mechanism of action of trastuzumab and scientific update." <i>Semin Oncol.</i> 28:4-11	
C03	BASELGA, 2001, "The EGFR as a target for anticancer therapy--focus on cetuximab." <i>Eur. J. Cancer</i> 37: S16-22	
C04	CARRAWAY & CANTLEY, "A new acquaintance for ErbB3 and ErbB4: a role for receptor heterodimerization in growth signaling." 1994, <i>Cell</i> 78:5-8	
C05	CIARDELLO et al., 2002, "A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor." <i>Clin. Cancer Res.</i> 7:2958-70	
C06	COUSSENS et al., 1985, "Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene." <i>Science</i> 230:1132-9	
C07	DEBONO et al., 2002, "The ErbB receptor family: a therapeutic target for cancer" <i>Trends in Mol. Med.</i> 8(4): S19-S26	
C08	FALLS, 2003, "Neuregulins: functions, forms, and signaling strategies." <i>Exp. Cell. Res.</i> 284(1): 14-30	
C09	FAN et al., 1994, <i>J. Biol. Chem.</i> 269:27585-602	
C10	GENBANK Accession No. AI001455, "Homo sapiens protooncogene protein (c-erb-2) gene, exon 1"	
C11	GENBANK Accession No. AY207002, "Homo sapiens neuregulin 1 isoform 4 (NRG1) mRNA, partial cds, alternatively spliced."	
C12	GENBANK Accession No. NM_004983, "Homo sapiens neuregulin 2 (NRG2) transcript variant 1 mRNA"	
C13	GENBANK Accession No. NM_013981, "Homo sapiens neuregulin 2 (NRG2) transcript variant 2 mRNA"	
C14	GENBANK Accession No. NM_013982, "Homo sapiens neuregulin 2 (NRG2) transcript variant 3 mRNA"	
C15	GENBANK Accession No. NM_013983, "Homo sapiens neuregulin 2 (NRG2) transcript variant 4 mRNA"	
C16	GENBANK Accession No. NM_013984, "Homo sapiens neuregulin 2 (NRG2) transcript variant 5 mRNA"	
C17	GENBANK Accession No. NM_013985, "Homo sapiens neuregulin 2 (NRG2) transcript variant 6 mRNA"	
C18	GENBANK Accession No. NM_031507, "Rattus norvegicus epidermal growth factor receptor (Egfr) mRNA"	

EXAMINER NYI-3927254v1	/Anne Holleran/	DATE CONSIDERED 12/22/2008
---------------------------	-----------------	-------------------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /A.H./



Express Mail No.: EV473971339US  
Sheet 2 of 3

LIST OF REFERENCES CITED BY APPLICANT  
(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.
6750-189-999	10/567,702
APPLICANT	
Richard Kim	
U.S. FILING DATE	ART UNIT
August 21, 2006	1642

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	(Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue number(s), publisher, city and/or country where published)	T
C19	GENBANK Accession No.: AF041702, "Gallus gallus tyrosine kinase ERBB-4 (ERBB4) mRNA, partial cds."	
C20	GENBANK Accession No.: M11762, "Homo sapiens protooncogene protein (c-erb-2) gene, exon 2"	
C21	GENBANK Accession No.: M11763, "Homo sapiens protooncogene protein (c-erb-2) gene, exon 3"	
C22	GENBANK Accession No.: M11764, "Homo sapiens protooncogene protein (c-erb-2) gene, exon 4."	
C23	GENBANK Accession No.: M11765, "Homo sapiens protooncogene protein (c-erb-2) gene, exon 5"	
C24	GENBANK Accession No.: M11766, "Homo sapiens protooncogene protein (c-erb-2) gene, exon 6."	
C25	GENBANK Accession No.: M11767, "Homo sapiens protooncogene protein (c-erb-2) gene, exon 7 and partial cds."	
C26	GOLDSTEIN et al., 1995, "Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model." <i>Clin. Cancer. Res.</i> 1:1311-8	
C27	GOUSTIN et al., 1986, "Growth factors and cancer." <i>Cancer Res</i> 46: 1015-29	
C28	HANCOCK et al., 1991, "A monoclonal antibody against the c-ErbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines." <i>Cancer Res.</i> 51:4575-80	
C29	LOGAN & SHENK, 1984, "Adenovirus tripartite leader sequence enhances translation of mRNAs late after infection." <i>Proc. Natl. Acad. Sci USA</i> 81:3655	
C30	NOONBERG et al., 2000, "Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily: role as anticancer agents." <i>Drugs</i> 59:753-67	
C31	OLAYIOYE et al., 2000, "The ErbB signaling network: receptor heterodimerization in development and cancer." <i>EMBO J.</i> 19:3159-67	
C32	PLOWMAN et al., 1990, "Molecular cloning and expression of an additional epidermal growth factor receptor-related gene." <i>Proc. Natl. Acad. Sci USA</i> 87:4905-9	
C33	PLOWMAN et al., 1993, "Ligand-specific activation of HER4/p180 <sup>erbB4</sup> , a fourth member of the epidermal growth factor receptor family." <i>Proc. Natl. Acad. Sci USA</i> 90:1746-50	
C34	PREWETT et al., 1996, "The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma." <i>J. Immunother. Tumor. Immunol.</i> 19: 419-427	
C35	SAMPSON et al., 2000, "Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors." <i>Proc. Natl. Acad. Sci. USA</i> 97:7503-8	
C36	SCHLESSINGER, 2000, "Cell signaling by receptor tyrosine kinases." <i>Cell</i> 103:211-225	
C37	SEDLACEK, 2000, "Kinase inhibitors in cancer therapy: a look ahead." <i>Drugs</i> 59:435-76	
C38	SIMON, 2000, "Receptor Tyrosine Kinases: Specific Outcomes from General Signals" <i>Cell</i> 103:13-15	
C39	TANG C.K. & LIPPMAN, M.E. in <i>Hormones and Signaling</i> , ed. O'Malley, B.W., 113-165, Academic Press, San Diego	
C40	ULRICH et al., 1984, "Search for selectivity in interactions of chiral solvated electrons." <i>Nature</i> 309:418-425	
C41	WELLS, 1999, "EGF receptor" <i>Int. J. Biochem &amp; Cell Biol.</i> 31:637-43	
C42	WOODBURN, 1999, "The epidermal growth factor receptor and its inhibition in cancer therapy." <i>Pharmacol. Ther.</i> 82:241-50	

EXAMINER NYI-3927254v1	/Anne Holleran/	DATE CONSIDERED 12/22/2008
---------------------------	-----------------	-------------------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /A.H./



Express Mail No.: EV473971339US  
Sheet 3 of 3

**LIST OF REFERENCES CITED BY APPLICANT**  
(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.
6750-189-999	10/567,702
APPLICANT	
Richard Kim	
U.S. FILING DATE	ART UNIT
August 21, 2006	1642

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	(Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue number(s), publisher, city and/or country where published)	T
C43	YANG et al., 2000, "Therapeutic Potential of ABX-EGF, a Fully Human Anti-EGF Receptor Monoclonal Antibody, for Cancer Treatment." <i>Proc. Am. Soc. Clin. Oncol.</i> 19:48	
C44	ZHANG et al., 1997, "Neuregulin-3 (NRG3): a novel neural tissue-enriched protein that binds and activates ErbB4." <i>Proc. Natl. Acad Sci USA</i> 94: 9562-7	

EXAMINER NYI-3927254v1	/Anne Holleran/	DATE CONSIDERED	12/22/2008
---------------------------	-----------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /A.H./

<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)	<b>ATTY. DOCKET NO.</b>	<b>APPLICATION NO.</b>
	<b>6750-189-999</b>	<b>10/567,702</b>
	<b>APPLICANT</b>	
	<b>Richard Kim</b>	
	<b>U.S. FILING DATE</b>	<b>ART UNIT</b>
	<b>February 2, 2006</b>	<b>1642 1643</b>

## U.S. PATENT DOCUMENTS

*Examiner Initial		Document Number	Date mm/dd/yy	Name Of Patentee Or Applicant Of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear

## FOREIGN PATENT DOCUMENTS

		Foreign Patent Document Country Code, Number, Kind Code (If Known)	Date mm/dd/yy	Name Of Patentee Or Applicant Of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue number(s), publisher, city and/or country where published)	T
/A.H./	C45	PCT International Search Report dated October 29, 2007, International App. No. PCT/US04/25545.	
/A.H./	C46	NORMANNO, N. et al. "Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment." <i>Endocrine-Related Cancer</i> . 2003, Vol. 10, pages 1-21.	
/A.H./	C47	BASELGA, J. et al. Phase I studies of Anti-Epidermal growth factor receptor chimeric antibody c225 alone and in combination with cisplatin. <i>February 2000</i> , Vol. 18, No. 4, pages 904-914.	

<b>EXAMINER</b> NYI-4046200v1	/Anne Holleran/	<b>DATE CONSIDERED</b>	12/14/2008
----------------------------------	-----------------	------------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /A.H./

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)		ATTY. DOCKET NO. 6750-189-999	APPLICATION NO. 10/567,702
		APPLICANT Richard Kim	
		U.S. FILING DATE August 21, 2006	ART UNIT 1643

**U.S. PATENT DOCUMENTS**

*Examiner Initial	Document Number	Date mm/dd/yy	Name Of Patentee Or Applicant Of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear

**FOREIGN PATENT DOCUMENTS**

	Foreign Patent Document Country Code, Number, Kind Code (If Known)	Date mm/dd/yy	Name Of Patentee Or Applicant Of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	(Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue number(s), publisher, city and/or country where published)				T	
/A.H./	C48	ANDERSON et al., 2002, "ErbB receptor tyrosine kinase inhibitors as therapeutic agents" <i>Front. Biosci.</i> 7:d1926-d1940				
/A.H./	C49	CAPPUZZO et al., 2003, "Gefitinib in pretreated non-small-cell lung cancer (NSCLC): Analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC" <i>J. Clin. Oncol.</i> 21:2658-2663				
/A.H./	C50	CHEN et al. 2000, "Enhanced drug resistance in cells coexpressing ErbB2 with EGF receptor or ErbB3" <i>Biochem. Biophys. Res. Comm.</i> 277: 757-763				
/A.H./	C51	CHRISTENSEN et al., 2001, "High levels of HER-2 expression alter the ability of epidermal growth factor receptor (EGFR) family tyrosine kinase inhibitors to inhibit EGFR phosphorylation in vivo" <i>Clin. Cancer Res.</i> 7:4230-4238				
/A.H./	C52	CLASSEN et al., 2002, "Clinical relevance of soluble c-erbB-2 for patients with metastatic breast cancer predicting the response to second-line hormone or chemotherapy" <i>Tumor Biol.</i> 23:70-75				
/A.H./	C53	NICHOLSON et al., 1993, "Relationship between EGF-R, c-erbB-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity" <i>Eur. J. Cancer</i> 29A:1018-1023				
/A.H./	C54	PATERSON et al., 1991, "Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer" <i>Cancer Res.</i> 51:556-567				
/A.H./	C55	XIA et al., 1999, "Combination of EGFR, HER-2/neu and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members" <i>Clin. Cancer Res.</i> 5:4164-4174				

EXAMINER NYI-4136908v1	/Anne Holleran/	DATE CONSIDERED 12/14/2008
---------------------------	-----------------	-------------------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /A.H./